Benefits of Applying QbD Concepts to Analytical Methods for Therapeutic Proteins Case Studies

Similar documents
Quality by Design in the Development of Analytical Procedures

Technical Procedure for Concentration Determination of Methamphetamine in Liquids via HPLC

Work plan & Methodology: HPLC Method Development

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

A Quality by Design (QbD) Based Method Development for the Determination of Impurities in a Peroxide Degraded Sample of Ziprasidone

Application Note. Author. Abstract. Pharmaceutical QA/QC. Vinayak A.K Agilent Technologies Bangalore, India

Transferring HPLC methods from the HP 1090 Series to the Agilent 1100 Series HPLC system

VALIDATION OF ANALYTICAL METHODS. Presented by Dr. A. Suneetha Dept. of Pharm. Analysis Hindu College of Pharmacy

FUSION METHOD DEVELOPMENT SOFTWARE

The Theory of HPLC. Quantitative and Qualitative HPLC

MODERN HPLC FOR PRACTICING SCIENTISTS

ELISA QUALITY ASSURANCE Analytical Phase

Appendix II- Bioanalytical Method Development and Validation

BECKMAN COULTER QbD1200 Total Organic Carbon Analyzer Critical Measurements Made Simple

Chapter 4: Verification of compendial methods

Successfully Scaling and Transferring HPLC and UPLC Methods

Prep 150 LC System: Considerations for Analytical to Preparative Scaling

Guideline/SOP: Handling of Laboratory Gross Errors/Data History

ASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES

serve the goal of analytical lmethod Its data reveals the quality, reliability and consistency of

ONDERSTEPOORT VETERINARY INSTITUTE METHOD: RTETH 042 DETERMINATION OF TETRACYCLINES IN HONEY 1. INTRODUCTION 2. EQUIPMENT

Assay Transfer from HPLC to UPLC for Higher Analysis Throughput

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: , ISSN(Online): Vol.9, No.7, pp , 2016

Method Validation Characteristics through Statistical Analysis Approaches. Jane Weitzel

Fasted State Dissolution Protocol

Supplementary information 1. INSTRUCTIONS FOR STUDENTS

Application Note. Pharmaceutical QA/QC. Author. Abstract. Siji Joseph Agilent Technologies, Inc. Bangalore, India

Perfluorinated Alkyl Acids (PFAA) in Water by LC/MS/MS - PBM

RESOLUTION OENO 33/2004 DETERMINATION OF SHIKIMIC ACID IN WINE BY HPLC AND UV-DETECTION

Quality by Design and Analytical Methods

And how to do them. Denise L Seman City of Youngstown

RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet formulation

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

Method Transfer between HPLC and UHPLC Instruments Equipment-related challenges and solutions

Micro Volume QuEChERS kit

Quantification of growth promoters olaquindox and carbadox in animal feedstuff with the Agilent 1260 Infinity Binary LC system with UV detection

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

HIPPURIC ACID and o-m-p- METHYLHIPPURIC ACIDS IN URINE BY UV CODE Z06010

METHOD 9040B. ph ELECTROMETRIC MEASUREMENT

ION CHROMATOGRAPHY SYSTEM S 150

Development And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk

Scope: Materials: Labeled 1.5 ml or 2 ml Eppendorf tubes Appropriate pipette tips (see Table 1) Labeled LC vials

Experimental design. Matti Hotokka Department of Physical Chemistry Åbo Akademi University

Laboratory Techniques 100: Back To Basics. Carol Injasoulian Lab Manager City of Bay City April 29,2015

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

Journal of Chemical and Pharmaceutical Research, 2017, 9(1): Research Article

Review Article Analytical Quality by Design Approach to Test Method Development and Validation in Drug Substance Manufacturing

Anion and Cation analysis with Professional IC - automatic dilution and sample preparation with SPM

PROCEDURES. Pharmacopeial Forum 2 Vol. 36(1) [Jan. Feb. 2009]

Certified Reference Material - Certificate of Analysis

Analytical Performance & Method. Validation

VMA, HVA, 5-HIAA Urine LC-MS/MS Analysis Kit User Manual

Optical density measurements automatically corrected to a 1-cm pathlength with PathCheck Technology

Quantitative Analysis of EtG and EtS in Urine Using FASt ETG and LC-MS/MS

Certified Reference Material - Certificate of Analysis

A Unified Approach to Uncertainty for Quality Improvement

Casein (Bovine) ELISA Kit

High Performance Liquid Chromatography

Chapter-4 EXPERIMENTAL WORK BY RP-HPLC

Volume 6, Issue 2, January February 2011; Article-015

Quantitative Analysis of EtG and EtS in Urine Using FASt ETG and LC-MS/MS

Certified Reference Material - Certificate of Analysis Methylone, Primary Standard

Sulfotepp impurities in Chlorpyrifos EC formulations

FUSION QBD. QbD-aligned LC Method Development with Fusion QbD

Part IVB Quality Assurance/Validation of Analytical Methods

How to develop an ATP.... and verify it has been met. Melissa Hanna-Brown Analytical R & D; Pfizer Global R+D, Sandwich UK.

Analytical method development and validation of gabapentin in bulk and tablet dosage form by using UV spectroscopic method

Application Note PB 401. Improve HPLC Sample Preparation in an Analytical Laboratory A New Automated Sample Preparation Process

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

DEVELOPMENT AND VALIDATION OF GC-FID METHOD FOR THE DETERMINATION OF ETHANOL RESIDUE IN MARJORAM OINTMENT

Determination of Caffeine by HPLC

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

ProPac WCX-10 Columns

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Human IL-1 beta ELISA Kit

Definitive EtG/EtS LC-MS/MS Analysis:

Determination of Trace Cations in Power Plant Waters Containing Morpholine

STANDARD OPERATING PROCEDURES SOP: 1828 PAGE: 1 of 14 REV: 0.0 DATE: 05/12/95 ANALYSIS OF METHYL PARATHION IN CARPET SAMPLES BY GC/MS

H 3 CO H 3 CO S CH 3

NECi Nitrate Kits FAQs

Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)

Clinical Chemistry Quality Control Policies, Processes, & Procedures

Rapid Screening and Confirmation of Melamine Residues in Milk and Its Products by Liquid Chromatography Tandem Mass Spectrometry

Bovine FSH(Follicle Stimulating Hormone) ELISA Kit

Pig IgG ELISA. Cat. No. KT-516 K-ASSAY. For the quantitative determination of IgG in pig biological samples. For Research Use Only. 1 Rev.

Achieve confident synthesis control with the Thermo Scientific ISQ EC single quadrupole mass spectrometer

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Barry E. Boyes, Ph.D. Consumables and Accessories Business Unit May 10, 2000

Simplifying the Process: Automated USP 643 / EP

To control the consistency and quality

Implementing principles of Quality by Design (QbD) in validation context

Technical Procedure for Blood Cannabinoid Liquid-Liquid Extraction (BCLLE) for Analysis by LC-MS/MS

HPLC Sample Preparation

Impact factor: 3.958/ICV: 4.10 ISSN:

Dog IgM ELISA. Cat. No. KT-458 K-ASSAY. For the quantitative determination of IgM in dog biological samples. For Research Use Only. 1 Rev.

Pharmacopeial Forum Vol. 36(1) [Jan. Feb. 2010] 1

METHOD 7060A ARSENIC (ATOMIC ABSORPTION, FURNACE TECHNIQUE)

Bisphenol A ELISA Kit

Automated, intelligent sample preparation: Integration of the ESI prepfast Auto-dilution System with the Thermo Scientific icap 7400 ICP-OES

Validation of HPLC Instrumentation

Transcription:

Benefits of Applying QbD Concepts to Analytical Methods for Therapeutic Proteins Case Studies Annick GERVAIS, PhD Analytical Sciences Biologicals, UCB CASSS AT Europe, Vienna, 17 March 2016

QbD for Analytical Methods Why? 2 Analytical methods are key elements of the Control Strategy (ICH Q10) to determine and measure (Critical) Quality Attributes. Understand performance QbD will bring the systematic methodology to ensure the right method at the right time Sources of Variability QbD of method Robust Life Cycle Management

QbD for Analytical Methods What does this mean? 3 Process Target Product Profile // Analytical method Analytical Target Profile Analytical Method LifeCycle Management 1 Critical Quality Attributes Risk Assessment Critical Method Attributes Risk Assessment Stage 1: Method Design & Understanding Design Space Method Operable Design Region (MODR) Control Strategy Continued Process Verification Control Strategy Continued Method Verification Stage 2: Method Performance Qualification Stage 3: Continued Method Verification ICHQ8 Pharmaceutical Development ICHQ9 Quality Risk Management 1 P. Nethercote et al. Pharm. Tech (2010), 34, 2; USP Stimuli to the Revision Process on Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification and Procedure Performance Verification (2013)

Analytical QbD in Practice 4 Analytical Target profile Method Performance Acceptance Criteria Critical method attributes Risk assessment MODR* Control Strategy DoE Predictive rather than descriptive approach Continued method verification Using trending tools & predictive tools *MODR = Method Operable Design Region

Stage 1 Method Design & Understanding

Analytical Target Profile 6 Definition The ATP defines the objective of the test & quality requirements for the reportable result. It is a prospective summary of the required characteristics of the reportable result that needs to be achieved to ensure the data is fit for purpose. Example : CEX-HPLC method for charge variants of product X The method must be able to determine the relative quantity of monomer peak and charge variants (acidic species (APG) & basic species (BPG)) in DS and DP samples. The method must be: - Specific, no interfering peak from buffers / matrix observed at the retention time of the isoforms - Accuracy profile: acceptance limit 30% at 5% risk for monomer and 50% at 5% risk for APG & BPG. - QL of APG & BPG must be at least 5% - Prepared sample must be at least stable for 72 hours at 5±3 C - Stability-indicating

Technology Selection 7 The method performance requirements defined in the ATP will guide the technology selection. It is key to consider also business drivers: - Cost - Analysis time - Supply continuity - Applicability in different QC labs and different regions

Critical Method Attributes 8 Identification of the critical method parameters: Start from prior knowledge on similar methods Use Ishikawa tools to classify the method parameters C N Classification of Attributes can be Controlled Noise cannot be controlled/ predicted Autosampler temperature Degassing of solution HPLC vials/caps Pipette technique Samples Method Run time Flow rate Syringe draw rate Solvent composition Buffer/Samplepreparation (dilution,...) Eppendorf tubes Solvent (salts, Water,...) Pipettes tips Column temperature Column conditioning Injector volume Shutdown method Column rinsing Column storage + injection number Filter HPLC material (fittings, tubing,...) Magnet stirrer Weighing materials Column / guard column Control/ref samples Calibration solutionsfor ph Gradient mode (comp, slope,...) Detection wavelength Sampling rate Sequence Reagents (mobile phase) General lab glassware Software use Prepared sample stability Manpower Data handling Pipette technique /Lab Handling Equipment preparation (rinsing step,...) Integration (manual/automatic) Control chart Measuring Cell T C Processing Method Instrument use (column installation,...) Method use Manual Integration Sample acceptance critera Calculation Automatic Integration SST (control sample + blank) Power Grid Environment Vibrations Detector Balance Magnetic stirrer Purified water system Fridge/Freezer Pipettes Vacuum filtration system Humidity HPLC autosampler HPLC injector Temperature Light Void volume Degasser ph meter Vortex mixer Ultrasonic bath Timer Software (comparability) X Instrument qualification HPLC pump pressure and flow rate capacity Column oven Experimentally defined Quality of analytical method data Material Measurement Instrument

Probability Risk Assessment Use of FMEA 9 Risk = Relevance x Probability Relevance 2 4 6 8 10 2 4 8 12 16 20 4 8 16 24 32 40 6 12 24 36 48 60 8 16 32 48 64 80 10 20 40 60 80 100 Risk value Table (relevance x probability) Effect Value Mitigation Color Low x 12 Optional Green Medium 12 < x < 40 Recommended to mitigate if possible Yellow High 40 Must mitigate Red

Risk Assessment Use of FMEA 10 Risk = Relevance x Probability Relevance Table Score Effect Description 2 Negligible Very low possibility of an impact on the quality of analytical method data 4 Minor 6 Moderate 8 Significant 10 Severe Slight possibility of an impact on the quality of analytical method data Possible impact on the quality of analytical method data Likely impact on the quality of analytical method data Strong likelihood of an impact on the quality of analytical method data Probability Table Score Effect Description Not certain that this will ever happen. Chances that it occurs one day are zero or close 2 to zero. Very unlikely For example: 1x per 1000 reportable result or 0,1% chance that it happens. 4 Unlikely Not certain that this will ever happen. Chances that it occurs one day are very low. For example: 1x per 100 reportable result or 1% chance that it happens. 6 Possible Not certain that this will ever happen. Chances that it occurs one day however are real. For example: 1X per 50 reportable result or 2% chance that it happens. 8 Likely It is certain that this is happening. Estimated frequency of its occurrence are estimated For example: 1x per 20 reportable result. or 5% chance that it happens. 10 Very likely It is certain that this is happening. Estimated frequency of its occurrence are estimated For example: 1x per 5 reportable result or 20% chance that it happens.

Example of CEX-HPLC method for Charge Variants 11 Mitigation plan Initial scoring Scoring after mitigation Category Method Attributes Potential Failure mode Instrument Environment Manpower Measurement Material Method Probabilit Risk Relevance y scoring Potential impact on method Classifica Relevan Probabi after after after performance tion ce lity Risk scoring Mitigation mitigation mitigation mitigation 8 4 32 8 4 32 8 4 32 8 4 32 6 6 36 6 6 8 4 32 8 2 16 8 4 32 8 2 16 8 4 32 8 2 16 8 4 32 8 2 16 8 4 32 8 2 16 10 6 60 10 4 40 8 4 32 8 2 16 10 2 20 10 2 20 4 2 8 2 2 4 6 2 12 6 2 12 8 2 16 8 2 16 6 2 12 6 2 12 8 8 64 8 4 32 10 6 60 10 4 40 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 8 6 48 8 2 16 0 0 0 0 6 4 24 0 8 6 48 6 2 12 10 6 60 10 4 40 0 0 8 4 32 8 2 16 8 6 48 0 8 6 48 0 0 0 0 0 0 0 8 4 32 8 2 16 8 6 48 0 8 4 32 0 6 4 24 0 6 4 24 0 8 4 32 8 2 16 8 4 32 6 2 12 8 4 32 0 10 10 100 0 10 10 100 0 0 6 6 36 0 6 6 36 0 10 10 100 0 6 6 36 6 4 24 6 6 36 0 8 6 48 0 6 4 24 0 8 4 32 8 2 16 8 4 32 8 2 16 8 4 32 8 2 16 6 6 36 6 4 24 For method attributes that can be experimentally defined (X), definition of MODR using Designs of Experiments (DoE) Iterative process

Critical Method Attributes - MODR 12 Design of experiments (DOE) is a test or series of tests in which purposeful changes are made to the input variables of a process so that we may observe and identify corresponding changes in the output response from Douglas Montgomery Introduction to statistical quality control ATTRIBUTE X Amount of enzyme DigestionTemperature Digestion duration Analytical method RESPONSE %Peak Area Experiments/assays variability.. NOISE (N) Use of DoE to: Evaluate effect of the most influencial parameters Identify the interactions between parameters Optimise the best operating condition settings

Critical Method Attributes - MODR 13 Screening designs Influent factors determination/ranking Eg Plackett & Burman Screening design Main influent factors determination Factorial designs Factors effects/interaction characterization Optimisation design Main factor & interactions Response surface designs Prediction in a domain Robustness design Small variations Eg Central Composite Design

Screening Design 14 Example of RP-HPLC method for a product related impurity Factors (chromatographic conditions): %TFA in mobile phase A %TFA in mobile phase B % ACN in mobile phase B % IPA in mobile phase B Flow rate Wavelength Column temperature Responses: %product related impurity Model: Plackett & Burman (only main effects) 12 runs Run %TFA in A %TFA in B %ACN %IPA Flow rate 1 1-1 -1 1 1-1 1 l Colum n T 2 1 1 1-1 -1-1 -1 3 1 1-1 1-1 -1 1 4 1-1 1-1 1 1-1 5-1 -1-1 1 1-1 -1 6 1 1 1-1 1 1 1 7 1-1 -1 1-1 1-1 8-1 1-1 1-1 1-1 9-1 1 1-1 1-1 -1 10-1 -1 1-1 -1-1 1 11-1 -1 1-1 -1 1 1 12-1 1-1 1 1 1 1

Screening Design Example of RP-HPLC method for a product related impurity 15 Prediction intervals chromatographic conditions Prediction intervals - sample preparation

Optimisation Design 16 Example of size variant method (SE-HPLC) Factors: NaCl in mobile phase [250 mm 350 mm] NaPO4 in mobile phase [90 mm 110 mm] ph of mobile phase [6.8 7.2] Column temperature [27 C 33 C] Responses: %HMWS % main peak ("monomer") %LMWS Model: Central Composite Design with 3 central points Full Factorial Design with replicate points 22 runs

Stage 2 Method Performance Qualification

Variabiliy Variabiliy Mean Mean Method Validation 18 From Descriptive to Predictive Approach Method Driven classical validation Data Driven Total Error % Bias< 10% % CV< 10% % Bias< 10% Will the method provide good results? % CV< 10% «Good» methods do NOT necessarily provide «good» results «Good» results can only be obtained by «good» methods What is important is the result, not the assay!

Method Validation 19 From Descriptive to Predictive Approach Total Error µ T x i - µ T = Systematic Error + Random Error = Bias + Standard Deviation = Trueness + Precision = Measurement Error = Accuracy 1 1 Accuracy = the closeness of agreement between an individual result found and the true value

Method Validation 20 From descriptive to Predictive Approach β-expectation tolerance limits 1 Acceptance Limits Relative bias The method is considered accurate within the range for which the accuracy profile is within the predefined acceptance limits. This Total Error Approach gives the guarantee that each future measurement of unknown samples is included within the tolerance limits with a given risk level (usually 5%) 1 The β-expectation tolerance interval is the interval wherein each future measurement will fall with a defined probability β. It represents the location where β% of the future results are expected to lie.

Method Validation by Total Error Approach 21 Example 1 : Validation of a RP-HPLC method for product related species Reportable result: %area of product related species X Risk = 5% Acceptance limits = 35% Expected %product related species X Expected %product related species X Use of E-Noval software - Arlenda

Method Validation by Total Error Approach 22 Example 2 : Validation of HCP ELISA assay Risk = 5% Acceptance limits = 30% LQL = 10.6ng/mL Use of E-Noval software - Arlenda

Stage 3 Continued Method Verification

Analytical Control Charts 24 Control strategy includes the use of control charts as follows: Use a control sample in each analytical run Report the parameters of interest measured on the control sample: Reportable result from the method Resolution, etc.. Trend these parameters using control charts Benefits of this control strategy: Determine if results performed on a routine basis are/remain acceptable for the intended purposes of the method. Allow anticipating drifts in the analytical methods. Allow comparing the performance of a method over time and also between laboratories/testing sites.

Analytical Control Charts 25 Example of Exponential Weighted Moving Average (EWMA) charts. EWMA upper limit UCL EWMA line LCL Date of analysis (chronological order) EWMA lower limit Trending Rules : Value outside of [LCL; UCL]: invalid analysis EWMA line crossing EWMA limits: out of trend LCL, UCL temporary fixed after 10 runs, and permanently fixed after 30 runs.

Conclusion

Conclusions 27 QbD for analytical methods is a systematic methodology based on three stages: Stage 1 method design and understanding: ATP, risk assessment, DoE to define the MODR for critical method attributes Stage 2 method performance qualification: Use predictive rather than descriptive approach: total error approach Stage 3 method continuous verification Use of analytical control charts for method performance trending It is an iterative process Applying QbD to analytical methods shows clear benefits in terms of: Method understanding Method robustness Ensuring to produce consistent and reliable data throughout the method lifecycle

THANKS TO 28 Method Development Team Aurélie DELANGLE Christophe BEAUFAYS Cyrille CHÉRY Grégory SCHITTEKATTE Jérémie CUISENAIRE Julie BRAUN Marc JACQUEMIN Marc SPELEERS Sandrine VAN LEUGENHAEGHE All other team members Statistician Team Bianca TEODORESCU Dimitris GAYRAUD Anastasia KOKOREVA Carl JONE Lance SMALLSHAW Chinedu MADICHIE